Nurix Therapeutics, Inc. (NRIX)
25.46
-0.36
(-1.39%)
USD |
NASDAQ |
Sep 03, 12:49
Nurix Therapeutics Research and Development Expense (TTM) : 332.34M for May 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| May 31, 2026 | 332.34M |
| February 28, 2026 | 322.79M |
| November 30, 2025 | 308.16M |
| August 31, 2025 | 291.93M |
| May 31, 2025 | 260.93M |
| February 28, 2025 | 231.67M |
| November 30, 2024 | 212.31M |
| August 31, 2024 | 195.42M |
| May 31, 2024 | 188.24M |
| February 29, 2024 | 185.51M |
| November 30, 2023 | 181.62M |
| August 31, 2023 | 178.32M |
| May 31, 2023 | 178.72M |
| February 28, 2023 | 181.07M |
| Date | Value |
|---|---|
| November 30, 2022 | 179.15M |
| August 31, 2022 | 170.44M |
| May 31, 2022 | 154.34M |
| February 28, 2022 | 133.52M |
| November 30, 2021 | 113.73M |
| August 31, 2021 | 97.76M |
| May 31, 2021 | 85.89M |
| February 28, 2021 | 74.15M |
| November 30, 2020 | 64.26M |
| August 31, 2020 | 56.74M |
| May 31, 2020 | 48.81M |
| February 29, 2020 | 45.32M |
| November 30, 2019 | 42.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Monte Rosa Therapeutics, Inc. | 162.57M |
| Gilead Sciences, Inc. | 5.943B |
| TG Therapeutics, Inc. | 225.80M |
| Cue Biopharma, Inc. | 76.97M |
| Keros Therapeutics, Inc. | 75.78M |